NASDAQ · Financial Statements
Astria Therapeutics, Inc. (ATXS) Financial Statements
$12.58
NASDAQ: ATXS
Market Cap $718.13M
Overview Financials Dividend Astria Therapeutics, Inc. most recently reported annual revenue of $0, net profit of $-94.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2020 2021 2022 2023 2024 Revenue $0 $0 $0 $0 $0 Operating Profit $-37.0M $-195.0M $-54.0M $-83.0M $-112.0M Net Profit $-37.0M $-195.0M $-52.0M $-73.0M $-94.0M EPS $-12.20 $-24.58 $-3.55 $-2.42 $-1.68 Op Margin — — — — —
Balance Sheet (USD)
Metric 2020 2021 2022 2023 2024 Total Assets $47.0M $128.0M $231.0M $255.0M $342.0M Total Liabilities $7.0M $5.0M $9.0M $12.0M $23.0M Cash $25.0M $87.0M $21.0M $176.0M $60.0M Borrowings $1.0M $0 $1.0M $0 $5.0M
Cash Flow (USD)
Metric 2020 2021 2022 2023 2024 Operating Cash Flow $-32.0M $-30.0M $-44.0M $-68.0M $-81.0M Investing Cash Flow $6.0M $-13.0M $-167.0M $135.0M $-192.0M Financing Cash Flow $0 $0 $0 $0 $5.0M Net Cash Flow $15.0M $62.0M $-66.0M $155.0M $-116.0M Free Cash Flow $-33.0M $-30.0M $-44.0M $-68.0M $-82.0M
Valuation & Return Ratios
Metric Value PEG Ratio 0.90 EV / EBITDA -6.36 FCF Yield -14.34% Quick Ratio 10.78 Interest Coverage 0.00 Return 1Y — Return 3Y — Return 5Y —
Screens featuring this stock